Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;31(31):5061-5082.
doi: 10.2174/0109298673288458240203064112.

Natural Products in Liver Fibrosis Management: A Five-year Review

Tao Wang  1 , Zhuo Lu  2 , Gui-Feng Sun  1 , Kai-Yi He  1 , Zhi-Ping Chen  3 , Xin-Hui Qu  4 , Xiao-Jian Han  1   4
Affiliations
Review

Natural Products in Liver Fibrosis Management: A Five-year Review

Tao Wang et al. Curr Med Chem. 2024.

Abstract

Liver fibrosis, characterized by the overproduction of extracellular matrix proteins within liver tissue, poses a rising global health concern. However, no approved antifibrotic drugs are currently available, highlighting the critical need for understanding the molecular mechanisms of liver fibrosis. This knowledge could not only aid in developing therapies but also enable early intervention, enhance disease prediction, and improve our understanding of the interaction between various underlying conditions and the liver. Notably, natural products used in traditional medicine systems worldwide and demonstrating diverse biochemical and pharmacological activities are increasingly recognized for their potential in treating liver fibrosis. This review aims to comprehensively understand liver fibrosis, emphasizing the molecular mechanisms and advancements in exploring natural products' antifibrotic potential over the past five years. It also acknowledges the challenges in their development and seeks to underscore their potency in enhancing patient prognosis and reducing the global burden of liver disease.

Keywords: Liver fibrosis; antifibrosis; etiology; hepatic stellate cell; immune cells.; molecular mechanism; natural product.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Berumen J.; Baglieri J.; Kisseleva T.; Mekeel K.; Liver fibrosis: Pathophysiology and clinical implications. WIREs Mech Dis 2021,13(1),e1499 - DOI - PubMed
    1. Kim D.; Li A.A.; Perumpail B.J.; Gadiparthi C.; Kim W.; Cholankeril G.; Glenn J.S.; Harrison S.A.; Younossi Z.M.; Ahmed A.; Changing trends in etiology-based and ethnicity-based annual mortality rates of cirrhosis and hepatocellular carcinoma in the United States. Hepatology 2019,69(3),1064-1074 - DOI - PubMed
    1. Ciardullo S.; Monti T.; Perseghin G.; High prevalence of advanced liver fibrosis assessed by transient elastography among U.S. adults with type 2 diabetes. Diabetes Care 2021,44(2),519-525 - DOI - PubMed
    1. Seki E.; Brenner D.A.; Recent advancement of molecular mechanisms of liver fibrosis. J Hepatobiliary Pancreat Sci 2015,22(7),512-518 - DOI - PubMed
    1. Demir Y; Ceylan H; Turkes C; Beydemir S; Molecular docking and inhibition studies of vulpinic, carnosic and usnic acids on polyol pathway enzymes. J Biomol Struct Dyn 2022,40(22),12008-12021

MeSH terms

  NODES
twitter 2